Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money?

Date: December 11, 2025

Journal: Health Affairs Forefront

Citation: Neumann PJ, Cohen JT, Sullivan S, Xie F. "Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money?", Health Affairs Forefront, December 11, 2025 . DOI: 10.1377/forefront.20251209.237091

CEVR offers its thoughts on CMS’s most recent round of negotiated drug prices and whether they align with value.

Supplemental materials – here.
• Annotated endnotes
• Computations for commentary Exhibit 1

Read Original Publication

More Publications

The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative?

View Publication

When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013–2023

View Publication

The Unintended Consequences of the Inflation Reduction Act on Biosimilar Market Incentives and Medicare Savings

View Publication

View All Publications